| scholarly article | Q13442814 |
| P2093 | author name string | Kevan M. Shokat | |
| Arvin C. Dar | |||
| P2860 | cites work | Gastrosplenic fistula from Hodgkin's lymphoma | Q83810390 |
| The Structure of the Potassium Channel: Molecular Basis of K + Conduction and Selectivity | Q22337058 | ||
| An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 | ||
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface | Q24301761 | ||
| A protein kinase involved in the regulation of inflammatory cytokine biosynthesis | Q24311139 | ||
| Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation | Q24314737 | ||
| CASK Functions as a Mg2+-independent neurexin kinase | Q24323323 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex | Q24336704 | ||
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling | Q24599676 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| A molecular mechanism for the effect of lithium on development | Q24629067 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty | Q27644039 | ||
| The Pseudoactive Site of ILK Is Essential for Its Binding to α-Parvin and Localization to Focal Adhesions | Q27646573 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase | Q27651185 | ||
| Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases | Q27652488 | ||
| Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation | Q27652602 | ||
| The unfolded protein response signals through high-order assembly of Ire1 | Q27653139 | ||
| Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site | Q27653415 | ||
| Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations | Q27654059 | ||
| A new screening assay for allosteric inhibitors of cSrc | Q27655292 | ||
| Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1 | Q27657237 | ||
| Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors | Q27658951 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237 | Q27660936 | ||
| Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 | Q27746054 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| A quantitative analysis of kinase inhibitor selectivity | Q28264038 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| A synthetic inhibitor of the mitogen-activated protein kinase cascade | Q28367955 | ||
| Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor | Q28368986 | ||
| Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition | Q28474624 | ||
| The cellular response to neuregulins is governed by complex interactions of the erbB receptor family | Q28609130 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| A chemical switch for inhibitor-sensitive alleles of any protein kinase | Q29614785 | ||
| Protein kinases--the major drug targets of the twenty-first century? | Q29615339 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Rational design of inhibitors that bind to inactive kinase conformations | Q29617558 | ||
| Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation | Q29617586 | ||
| SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 | Q29620495 | ||
| Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma | Q30494625 | ||
| Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes | Q33612296 | ||
| Targeting the cancer kinome through polypharmacology | Q33893019 | ||
| A common mechanism of action for three mood-stabilizing drugs | Q34128871 | ||
| Emerging roles of pseudokinases | Q34552850 | ||
| Protein tyrosine kinases: autoregulation and small-molecule inhibition | Q35035242 | ||
| Protein kinase structure and function analysis with chemical tools. | Q36280690 | ||
| Inhibitor hijacking of Akt activation | Q39847621 | ||
| Structural bioinformatics-based design of selective, irreversible kinase inhibitors | Q40307105 | ||
| Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo | Q40409799 | ||
| Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors | Q40509516 | ||
| Paradoxical activation of Raf by a novel Raf inhibitor | Q40939473 | ||
| Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. | Q40947866 | ||
| Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase Cdelta. | Q41845102 | ||
| Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase | Q42216028 | ||
| Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution | Q42541263 | ||
| Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake | Q42810034 | ||
| A specific inhibitor of the epidermal growth factor receptor tyrosine kinase | Q42834515 | ||
| Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. | Q42971539 | ||
| Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks | Q43096508 | ||
| Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites | Q43858813 | ||
| Bypassing a Kinase Activity with an ATP-Competitive Drug | Q44621093 | ||
| The effect of quercetin on the phosphorylatio activity of the Rous sarcoma virus transforming gene product in vitro and in vivo | Q45797796 | ||
| PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. | Q45998535 | ||
| Chemical genetics: where genetics and pharmacology meet | Q46192463 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| Pseudokinases: functional insights gleaned from structure. | Q54774270 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein evolution | Q59870539 |
| P1104 | number of pages | 27 | |
| P304 | page(s) | 769-795 | |
| P577 | publication date | 2011-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Annual Review of Biochemistry | Q567356 |
| P1476 | title | The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling | |
| The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling | |||
| P478 | volume | 80 |
| Q27684095 | A Genetically Encoded 19F NMR Probe for Tyrosine Phosphorylation |
| Q27676768 | A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A |
| Q92876695 | A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors |
| Q34582206 | A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. |
| Q42557545 | A chemical genetic approach to probe the function of PINK1 in regulating mitochondrial dynamics. |
| Q28539535 | A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination |
| Q27680722 | A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity |
| Q42292504 | A dynamic hydrophobic core orchestrates allostery in protein kinases. |
| Q39834894 | A visualizable chain-terminating inhibitor of glycosaminoglycan biosynthesis in developing zebrafish |
| Q39497293 | AEE788 Inhibits Basal Body Assembly and Blocks DNA Replication in the African Trypanosome |
| Q52309562 | AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. |
| Q91591513 | ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT |
| Q28553464 | ATP-Competitive MLKL Binders Have No Functional Impact on Necroptosis |
| Q41626312 | Akt3 is a privileged first responder in isozyme-specific electrophile response. |
| Q57287539 | Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors |
| Q98178435 | Allosteric Regulation at the Crossroads of New Technologies: Multiscale Modeling, Networks, and Machine Learning |
| Q35745479 | Anchor-based classification and type-C inhibitors for tyrosine kinases |
| Q50969031 | Aptamers as Valuable Molecular Tools in Neurosciences. |
| Q38127513 | B cell receptor signaling in chronic lymphocytic leukemia |
| Q30370399 | BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity. |
| Q58589636 | Bitopic Inhibition of ATP and Substrate Binding in Ser/Thr Kinases through a Conserved Allosteric Mechanism |
| Q49315568 | Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights |
| Q38083077 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). |
| Q35181271 | Bruton's TK inhibitors: structural insights and evolution of clinical candidates |
| Q41813875 | Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells |
| Q34342905 | Chemistry-based functional proteomics for drug target deconvolution |
| Q24294846 | Crystal structure of the Golgi casein kinase |
| Q47735630 | DNA-Encoded Chemical Libraries: A Selection System Based On Endowing Organic Compounds with Amplifiable Information |
| Q37091873 | Death associated protein kinases: molecular structure and brain injury |
| Q36327175 | Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis |
| Q38681971 | Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket |
| Q55056451 | Design, Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib. |
| Q38030191 | Development and plasticity of the primary visual cortex |
| Q33605357 | Discoidin domain receptors in disease |
| Q38873500 | Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic |
| Q34703677 | Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. |
| Q27003966 | Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions |
| Q52668906 | Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations |
| Q30395364 | Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways |
| Q35033532 | Extracellular metabolic energetics can promote cancer progression |
| Q35894374 | Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. |
| Q55715063 | FIKK Kinase, a Ser/Thr Kinase Important to Malaria Parasites, Is Inhibited by Tyrosine Kinase Inhibitors. |
| Q92879928 | Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors |
| Q30393936 | Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor |
| Q35002775 | Generation and characterization of ATP analog-specific protein kinase Cδ. |
| Q54320260 | Highly efficient and selective phosphorylation of amino acid derivatives and polyols catalysed by 2-aryl-4-(dimethylamino)pyridine-N-oxides--towards kinase-like reactivity |
| Q37031799 | Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue |
| Q34313286 | Histone acetyltransferases: Rising ancient counterparts to protein kinases |
| Q35759866 | Identification and Characterization of an Irreversible Inhibitor of CDK2. |
| Q47384926 | Identification of Conserved Water Sites in Protein Structures for Drug Design. |
| Q59052323 | Identification of Plant Homologues of Dual Specificity Yak1-Related Kinases |
| Q35557270 | Identifying a kinase network regulating FGF14:Nav1.6 complex assembly using split-luciferase complementation |
| Q92863081 | In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs |
| Q27678182 | Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization |
| Q27679437 | Insights into Aurora-A Kinase Activation Using Unnatural Amino Acids Incorporated by Chemical Modification |
| Q36491218 | KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms |
| Q38107273 | Kinase Inhibitors of Marine Origin |
| Q37547710 | Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. |
| Q35509663 | Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q36203630 | Label-free electrochemical impedance detection of kinase and phosphatase activities using carbon nanofiber nanoelectrode arrays |
| Q34265511 | Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action |
| Q39930681 | MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR4. |
| Q42936824 | Marine derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors |
| Q27865268 | Mitogen-activated protein kinases in innate immunity |
| Q28548366 | Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution |
| Q27673353 | Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors |
| Q30391310 | Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation. |
| Q38335784 | Molecular recognition in chemical and biological systems |
| Q38265477 | New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013. |
| Q27681838 | Non-ATP-Mimetic Organometallic Protein Kinase Inhibitor |
| Q39171961 | Non-kinase targets of protein kinase inhibitors |
| Q38641286 | Nucleotide-binding mechanisms in pseudokinases |
| Q58696684 | Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors |
| Q39315792 | Optochemical Control of Biological Processes in Cells and Animals. |
| Q41694250 | Phorbol esters dPPA/dPA promote furin expression involving transcription factor CEBPβ in neuronal cells. |
| Q41787133 | Prediction of kinase-inhibitor binding affinity using energetic parameters |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q38968261 | Presence and utility of intrinsically disordered regions in kinases |
| Q28487785 | Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays |
| Q92237404 | Prospects for pharmacological targeting of pseudokinases |
| Q34554617 | Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents |
| Q38169198 | Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases |
| Q54977260 | Redefining the Protein Kinase Conformational Space with Machine Learning. |
| Q54542586 | Redox regulation: Taking AKTion on HNEs. |
| Q38285510 | Role of phosphoproteomics in the development of personalized cancer therapies |
| Q45722871 | Scaffold mining of kinase hinge binders in crystal structure database |
| Q58756797 | Structural Basis for the Inhibition of Cyclin G-Associated Kinase by Gefitinib |
| Q98196833 | Structural basis for polyglutamate chain initiation and elongation by TTLL family enzymes |
| Q30368961 | Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions. |
| Q38987589 | Structure-functional prediction and analysis of cancer mutation effects in protein kinases. |
| Q54627325 | Systems biology-embedded target validation: improving efficacy in drug discovery. |
| Q34015040 | Targeting DNA repair pathways for cancer treatment: what's new? |
| Q89697165 | Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles |
| Q51843085 | Tetramethylpyrazine induces G0/G1 cell cycle arrest and stimulates mitochondrial-mediated and caspase-dependent apoptosis through modulating ERK/p53 signaling in hepatic stellate cells in vitro |
| Q28821689 | The Die Is Cast: Precision Electrophilic Modifications Contribute to Cellular Decision Making |
| Q37080936 | The current state of the art of quantitative phosphoproteomics and its applications to diabetes research |
| Q26852588 | The dynamic nature of the kinome |
| Q36968220 | The importance of tau phosphorylation for neurodegenerative diseases |
| Q99616628 | Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity |
| Q46137978 | Triptolide-Assisted Phosphorylation of p53 Suppresses Inflammation-Induced NF-κB Survival Pathways in Cancer Cells |
| Q38729941 | Uncoupling Catalytic and Binding Functions in the Cyclic AMP-Dependent Protein Kinase A |
| Q39534317 | Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design? |
| Q48050086 | Visible-Light-Triggered Activation of a Protein Kinase Inhibitor |
| Q92284349 | Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection |
Search more.